I opfølgningsbehandlingen fik dog næsten 50% af patienterne fra armen med cetuximab- monoterapi en kombination af cetuximab og irinotecan efter progression af sygdommen, hvilket kan have påvirket den samlede overlevelsestid.
In the randomised trial, the improvement in overall survival time did not reach statistical significance; however, in the follow-up treatment, nearly 50% of the patients of the cetuximab alone arm received a combination of cetuximab and irinotecan after progression of disease, which may have influenced overall survival time.